The osmotic release oral system (OROS) methylphenidate formulation is a prolonged-
release medication for the treatment of attention-deficit/hyperactivity disorder (ADHD) in …

Controlled-delivery methylphenidate (methylphenidate CD)[Equasym™ XL, Metadate
CD™], an oral stimulant, is approved in the US and EU to treat children aged≥ 6 years who …

Objective: To assess the effect of Osmotic-Release Oral System (OROS) methylphenidate
(MPH) on a variety of measures evaluating academic performance, cognition, and social …

Purpose The aim of this study was to evaluate long-term clinical treatment with OROS®
methylphenidate (MPH)(Concerta®) in children and adolescents with attention …

Objectives: To study the safety and efficacy of the long-acting methylphenidate formulation
PRC-063 in adolescents with attention-deficit/hyperactivity disorder (ADHD). Methods …

This was a 1-month, multicenter, open-label, randomized study to determine single-and
multiple-dose pharmacokinetics of d, l-methylphenidate (MPH) after MPH transdermal …

Introduction Treatment options for adults with attention deficit hyperactivity disorder (ADHD)
are limited. The study was conducted to confirm the clinically effective and safe dose of …

Objective: To determine the pharmacokinetic (PK) profile of a proprietary formulation of
methylphenidate (MPH) in children and adolescents with attention-deficit/hyperactivity …

OBJECTIVE: The Preschool ADHD Treatment Study (PATS) was a NIMH-funded, six-center,
randomized, controlled trial to determine the efficacy and safety of immediate-release …

Objectives: HLD200, a once-daily, evening-dosed, delayed-release and extended-release
methylphenidate (DR/ER-MPH), was designed to provide therapeutic effect beginning upon …